Mr. Donovan has served as President and CEO of Tioma since joining the company in 2016. Mr. Donovan has more than two decades of industry experience, first as an investment banker and then as a member of senior leadership within several biotechnology companies. Prior to joining Tioma, Mr. Donovan was a co-founder of Alios BioPharma and served as its Chief Business Officer and Chief Financial Officer from January 2011 through its acquisition by Johnson & Johnson (November 2014) and ending in December of 2015. Prior to joining Alios, Mr. Donovan was Chief Financial Officer at CoMentis, a privately held biotechnology company. Previously, Mr. Donovan served as head of Strategic Planning & Corporate Communications at InterMune, a publicly traded biotechnology company (subsequently acquired by Roche), and he began his career as a corporate investment banker, first at Vector Securities International, a boutique life sciences investment bank, then at Banc of America Securities, a global, full-service investment bank. He received his Bachelors of Business Administration from the University of Notre Dame.
President and Chief Executive Officer
Pankaj Bhargava, M.D.
Chief Medical Officer
Dr. Bhargava is a medical oncologist and clinical pharmacologist who has been engaged in drug development for over two decades. He has held leadership roles in biotech and pharmaceutical companies, overseeing clinical development, pharmacovigilance, regulatory affairs and medical affairs. Prior to joining Tioma, he was Chief Medical Officer at Dicerna Pharmaceuticals where he was responsible for development across all therapeutic areas including oncology and rare diseases. Previously, he was Associate Vice President at Sanofi Oncology, where he led the global development of Zaltrap™ (aflibercept), culminating in successful approvals by the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) and multiple agencies worldwide. Prior to Sanofi, Dr. Bhargava was vice president of clinical research and interim Chief Medical Officer at AVEO Pharmaceuticals. Dr. Bhargava currently serves as an attending physician at Dana-Farber Cancer Institute and is an Assistant Professor (part-time) at Harvard Medical School. He is U.S. Board Certified in Internal Medicine, Medical Oncology and Clinical Pharmacology, and completed an advanced fellowship in Developmental Therapeutics at the Lombardi Cancer Center at Georgetown University, during which he served as a visiting fellow at the FDA Center for Drug Evaluation and Research (CDER).
Robert W. Karr, M.D.
Chief Scientific Officer
Dr. Karr has served as Chief Scientific Officer of Tioma since joining the company in 2010. Dr. Karr has extensive experience in the pharmaceutical and biotechnology industries with expertise ranging the spectrum of drug development, from discovery research to clinical trial execution. Prior to Tioma, Dr. Karr held senior management positions in Idera, Pfizer, and Warner-Lambert. Dr. Karr completed his internship and residency in internal medicine at Washington University School of Medicine and served as faculty member at both the University of Iowa College of Medicine and Washington University School of Medicine. He received his B.S. from Southwestern University in 1971 and his M.D. from the University of Texas Medical Branch in 1975.
Sanjay Chanda, Ph.D.
Chief Development Officer
Dr. Chanda has over twenty years of experience in drug development, including experience with product development, regulatory affairs, and product registration. Most recently, Dr. Chanda served as Senior Vice President, Drug Development at Anacor Pharmaceuticals until its acquisition by Pfizer in June of 2016. At Anacor, he was responsible for all aspects of CMC and Preclinical Safety and played key leadership roles in the development and approvals of KERYDIN® for the treatment of onychomycosis and EUCRISA® for the treatment of eczema. Previously, Dr. Chanda was Senior Director, Toxicology, Drug Metabolism and Pharmacokinetics at NeurogesX, Inc., prior to its acquisition by Acorda Therapeutics, where he played a leadership role in development of QUTENZA® for the management of neuropathic pain associated with postherpetic neuralgia. He also held industry positions at Cerus Corporation and PPD-Development. Dr. Chanda has over thirty publications in various peer-reviewed journals. Dr. Chanda received his PhD in Pharmacology/Toxicology at Northeast Louisiana University and completed postdoctoral fellowships at University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, North Carolina.
Chief Business Officer
Mr. Stutz has served as Chief Business Officer of Tioma since joining the company in 2016. He has over 15 years of experience in the life sciences industry in operating, venture capital and management consulting positions. Prior to joining Tioma, James was the Vice President of Strategy & Business Development at Alios BioPharma (acquired by Johnson & Johnson) where he was responsible for business development, strategic and financial planning. Before joining Alios, he was a Principal at Essex Woodlands, where he worked on numerous venture capital and growth equity transactions in the biopharmaceutical and life science tools space. James also held various business development, finance and planning positions at CoMentis and InterMune. Earlier in his career James was a Senior Consultant at Strategic Decisions Group and was a commissioned officer in the United States Air Force. He has a B.A. in Business Economics from the University of California, Santa Barbara, and a Master of Business Administration from the Tuck School of Business at Dartmouth. Since October 2012, he has held an appointment as a Lecturer at Stanford University in the Department of Medicine, Division of Clinical Pharmacology in the School of Medicine.
Pamela T. Manning, Ph.D.
Vice President of Research & Development
Dr. Manning has served as Vice President of Research & Development since co-founding Tioma (formerly Vasculox) in 2006. Prior to Tioma, Dr. Manning held director-level positions at Pharmacia and Pfizer. She has considerable experience developing drug candidates through IND-enabling studies and early clinical trials, with expertise in nitric oxide biochemistry and pharmacology. Dr. Manning holds B.S. and M.S. degrees from Wright State University and a Ph.D. in pharmacology from the Ohio State University.
Vice President of Clinical Operations
Mr. Hinds has served as Vice President of Clinical Operations since joining Tioma in 2016. He was previously Senior Director of Clinical Operations at Alios Biopharma (acquired by Johnson and Johnson). David has over 21 years of experience focused on the delivery of clinical programs across all phases on development and multiple therapeutic areas. He has held a variety of positions with small and large clinical research organizations as well as small and large pharma and biotech firms. He has directly contributed to the success of global products including Rituxan, Adcetris, and Velcade. He received a B.S. in Biology from The Citadel and a Master in Business Administration from the Darla Moore School of Business at the University of South Carolina.
William A. Frazier, Ph.D.
Scientific Founder and Advisor
Dr. Frazier is a professor of Biochemistry, Molecular Biophysics, Cell Biology, and Biomedical Engineering at Washington University School of Medicine. He discovered that CD47 is a receptor for thrombospondin-1. Having contributed to over 140 publications, Dr. Frazier has been a leader in the field of CD47-mediated signaling pathways for many years. He founded Tioma (formerly Vasculox) in 2006 based on research from his laboratory and that of his collaborators at the National Institutes of Health. Dr. Frazier holds a B.A. from Johns Hopkins University and a Ph.D. from Washington University in St. Louis.